 |
|
Long-term Effectiveness of Treatment With Terbinafine vs Itraconazole in Onychomycosis
A 5-Year Blinded Prospective Follow-up Study
Bárður Sigurgeirsson, MD, PhD;
Jón H. Ólafsson, MD, PhD;
Jón þ Steinsson, MD;
Carle Paul, MD;
Stephan Billstein, MD;
E. Glyn V. Evans, MD
Arch Dermatol. 2002;138:353-357.
Objective To examine long-term cure and relapse rates after treatment with continuous
terbinafine and intermittent itraconazole in onychomycosis.
Design Long-term prospective follow-up study.
Setting Three centers in Iceland.
Subjects The study population comprised 151 patients aged 18 to 75 years with
a clinical and mycological diagnosis of dermatophyte toenail onychomycosis.
Interventions In a double-blind, double-dummy study, patients were randomized to receive
either terbinafine (250 mg/d) for 12 or 16 weeks or itraconazole (400 mg/d)
for 1 week in every 4 for 12 or 16 weeks (first intervention). Patients who
did not achieve clinical cure at month 18 or experienced relapse or reinfection
were offered an additional course of terbinafine (second intervention).
Main Outcome Measures The primary efficacy criterion was mycological cure, defined as negative
results on microscopy and culture at the end of follow-up and no requirement
of second intervention treatment. Secondary efficacy criteria included clinical
cure without second intervention treatment and mycological and clinical relapse
rates.
Results Median duration of follow-up was 54 months. At the end of the study,
mycological cure without second intervention treatment was found in 34 (46%)
of the 74 terbinafine-treated subjects and 10 (13%) of the 77 itraconazole-treated
subjects (P<.001). Mycological and clinical relapse
rates were significantly higher in itraconazole vs terbinafine-treated patients
(53% vs 23% and 48% vs 21%, respectively). Of the 72 patients who received
subsequent terbinafine treatment, 63 (88%) achieved mycological cure and 55
(76%) achieved clinical cure.
Conclusion In the treatment of onychomycosis, continuous terbinafine provided superior
long-term mycological and clinical efficacy and lower rates of mycological
and clinical relapse compared with intermittent itraconazole.
From the Department of Dermatology, University of Iceland and Landspitali
University Hospital, Reykjavik, Iceland (Drs Sigurgeirsson and Ólafsson);
Húðlæknastöðin, Dermatology Center (Dr Steinsson); the
Department of Dermatology, Mulhouse Hospital, Mulhouse, France; Clinical Research,
Novartis Pharma AG, Basel, Switzerland (Dr Paul); Clinical Research, Novartis
Pharmaceutical Corporation, East Hanover, NJ (Dr Billstein); and Mycology
Reference Centre, University of Leeds and General Infirmary, Leeds, England
(Dr Evans).
RELATED ARTICLE
Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 2002;138(3):421-422.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
How should fungal nail infection be treated?
DTB 2008;46:3-8.
ABSTRACT
| FULL TEXT
Treatment of Toenail Onychomycosis with Oral Terbinafine Plus Aggressive Debridement: IRON-CLAD, a Large, Randomized, Open-Label, Multicenter Trial.
Jennings et al.
J. Am. Podiatr. Med. Assoc. 2006;96:465-473.
ABSTRACT
| FULL TEXT
Treatment of Onychomycosis in Diabetic Patients
Winston and Miller
Clin. Diabetes 2006;24:160-166.
ABSTRACT
| FULL TEXT
Evaluating Costs for Onychomycosis Treatments: A Practitioner's Perspective
Warshaw
J. Am. Podiatr. Med. Assoc. 2006;96:38-52.
ABSTRACT
| FULL TEXT
Fungal Infections of the Nail: New Perspectives
Bristow
INT J LOW EXTREM WOUNDS 2005;4:72-73.
Extra Copies of the Aspergillus fumigatus Squalene Epoxidase Gene Confer Resistance to Terbinafine: Genetic Approach to Studying Gene Dose-Dependent Resistance to Antifungals in A. fumigatus
Liu et al.
Antimicrob. Agents Chemother. 2004;48:2490-2496.
ABSTRACT
| FULL TEXT
Therapeutic Efficacy of Topically Applied KP-103 against Experimental Tinea Unguium in Guinea Pigs in Comparison with Amorolfine and Terbinafine
Tatsumi et al.
Antimicrob. Agents Chemother. 2002;46:3797-3801.
ABSTRACT
| FULL TEXT
|
